Janine Powers

702 total citations
12 papers, 317 citations indexed

About

Janine Powers is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Janine Powers has authored 12 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Janine Powers's work include Fibroblast Growth Factor Research (6 papers), CAR-T cell therapy research (3 papers) and Gastrointestinal Tumor Research and Treatment (3 papers). Janine Powers is often cited by papers focused on Fibroblast Growth Factor Research (6 papers), CAR-T cell therapy research (3 papers) and Gastrointestinal Tumor Research and Treatment (3 papers). Janine Powers collaborates with scholars based in United States, United Kingdom and Denmark. Janine Powers's co-authors include Alan J. Russell, Neyssa Marina, Zev A. Wainberg, Jason A. Holt, Daniel V.T. Catenacci, Andrew N. Billin, Guizhen Luo, Aaron C. Hinken, Hong Xiang and Ann‐Marie Schmidt and has published in prestigious journals such as Journal of Clinical Oncology, Circulation Research and Cancer Research.

In The Last Decade

Janine Powers

11 papers receiving 315 citations

Peers

Janine Powers
Chuntao Gao China
Changyoung Yoo South Korea
Kenta Mukaihara Japan
Zsombor Melegh United Kingdom
Mee‐Hye Oh South Korea
Pamela L. Lyle United States
Hang‐bo Zhou China
Anat Ohali Israel
Benjamin L. Green United States
Takayoshi Waki Japan
Chuntao Gao China
Janine Powers
Citations per year, relative to Janine Powers Janine Powers (= 1×) peers Chuntao Gao

Countries citing papers authored by Janine Powers

Since Specialization
Citations

This map shows the geographic impact of Janine Powers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janine Powers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janine Powers more than expected).

Fields of papers citing papers by Janine Powers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janine Powers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janine Powers. The network helps show where Janine Powers may publish in the future.

Co-authorship network of co-authors of Janine Powers

This figure shows the co-authorship network connecting the top 25 collaborators of Janine Powers. A scholar is included among the top collaborators of Janine Powers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janine Powers. Janine Powers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Noviski, Mark, Jun Ma, Ernestine Lee, et al.. (2022). Abstract 1126: Concurrent degradation of BTK and IMiD neosubstrates by NX-2127 enhances multiple mechanisms of tumor killing. Cancer Research. 82(12_Supplement). 1126–1126. 6 indexed citations
2.
Whelan, Sarah, Jordan Ye, Ganesh Cherala, et al.. (2022). 777 Initial clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies. Regular and Young Investigator Award Abstracts. A809–A809.
3.
Whelan, Sarah, Jennifa Gosling, Frederick Cohen, et al.. (2021). 98 NX-0255, a small molecule CBL-B inhibitor, expands and enhances tumor infiltrating lymphocytes (TIL) for use in adoptive cancer immunotherapy. Regular and Young Investigator Award Abstracts. A107–A107. 4 indexed citations
4.
Xiang, Hong, Ago Ahene, David I. Bellovin, et al.. (2021). Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. mAbs. 13(1). 1981202–1981202. 26 indexed citations
5.
Catenacci, Daniel V.T., Drew Rasco, Jeeyun Lee, et al.. (2020). Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. Journal of Clinical Oncology. 38(21). 2418–2426. 69 indexed citations
6.
Catenacci, Daniel V.T., Anteneh Tesfaye, Eric Cheung, et al.. (2019). Bemarituzumab With Modified Folfox6 For Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design. Future Oncology. 15(18). 2073–2082. 56 indexed citations
7.
Sharma, Khushboo, et al.. (2019). Abstract A033: Evaluation of FGFR2b in context of relevant biomarkers supports potential combination of anti-FGFR2b with anti-PD-(L)1 therapy in gastric cancer. Molecular Cancer Therapeutics. 18(12_Supplement). A033–A033. 3 indexed citations
8.
9.
Carleton, Michael, Janine Powers, Penny Phillips, et al.. (2018). Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.. Journal of Clinical Oncology. 36(15_suppl). 3020–3020. 11 indexed citations
10.
Hinken, Aaron C., Janine Powers, Guizhen Luo, et al.. (2016). Lack of evidence for GDF 11 as a rejuvenator of aged skeletal muscle satellite cells. Aging Cell. 15(3). 582–584. 63 indexed citations
11.
12.
Spiekerkoetter, Edda, Christophe Guignabert, Vinicio de Jesús Pérez, et al.. (2009). S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phospho–Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4. Circulation Research. 105(7). 639–647. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chuntao Gao Breakdown of academic impact, for papers by Changyoung Yoo Breakdown of academic impact, for papers by Kenta Mukaihara Breakdown of academic impact, for papers by Zsombor Melegh Breakdown of academic impact, for papers by Mee‐Hye Oh Breakdown of academic impact, for papers by Pamela L. Lyle Breakdown of academic impact, for papers by Hang‐bo Zhou Breakdown of academic impact, for papers by Anat Ohali Breakdown of academic impact, for papers by Benjamin L. Green Breakdown of academic impact, for papers by Takayoshi Waki
Rankless by CCL
2026